(Q37990356)

26 August 2017

title

Polycystic ovary syndrome and chronic inflammation: pharmacotherapeutic implications (English)

1 reference

polycystic ovary syndrome

26 August 2017

main subject

1 reference

1 reference

Susan Maureen Sirmans

1

1 reference

26 August 2017

Emily Weidman-Evans

2

1 reference

26 August 2017

Victoria Everton

3

1 reference

26 August 2017

Daniel Thompson

4

1 reference

26 August 2017

language of work or name

English

0 references

publication date

28 February 2012

1 reference

Annals of Pharmacotherapy

26 August 2017

published in

1 reference

26 August 2017

volume

46

1 reference

26 August 2017

issue

3

1 reference

26 August 2017

page(s)

403-418

1 reference

The prevalence and features of the polycystic ovary syndrome in an unselected population

26 August 2017

cites work

1 reference

Polycystic ovary syndrome is associated with negatively variable impacts on domains of health-related quality of life: evidence from a meta-analysis

21 January 2018

1 reference

21 January 2018

1 reference

Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome

21 January 2018

1 reference

Criteria for Defining Polycystic Ovary Syndrome as a Predominantly Hyperandrogenic Syndrome: An Androgen Excess Society Guideline

21 January 2018

1 reference

Body composition characteristics and fat distribution patterns in young infertile women

21 January 2018

1 reference

Relative risk of conversion from normoglycaemia to impaired glucose tolerance or non-insulin dependent diabetes mellitus in polycystic ovarian syndrome.

21 January 2018

1 reference

Epidemiology and adverse cardiovascular risk profile of diagnosed polycystic ovary syndrome

21 January 2018

1 reference

Prevalence and predictors of dyslipidemia in women with polycystic ovary syndrome

21 January 2018

1 reference

Cardiometabolic abnormalities in the polycystic ovary syndrome: pharmacotherapeutic insights

21 January 2018

1 reference

Prevalence of impaired glucose tolerance and diabetes in women with polycystic ovary syndrome.

21 January 2018

1 reference

Use of fasting blood to assess the prevalence of insulin resistance in women with polycystic ovary syndrome

21 January 2018

1 reference

Insulin resistance in patients with polycystic ovary syndrome is associated with elevated plasma homocysteine

21 January 2018

1 reference

Insulin resistance, polycystic ovary syndrome, and type 2 diabetes mellitus

21 January 2018

1 reference

Global fibrinolytic capacity is decreased in polycystic ovary syndrome, suggesting a prothrombotic state

21 January 2018

1 reference

Profound peripheral insulin resistance, independent of obesity, in polycystic ovary syndrome

21 January 2018

1 reference

Insulin secretory defects in polycystic ovary syndrome. Relationship to insulin sensitivity and family history of non-insulin-dependent diabetes mellitus

21 January 2018

1 reference

Prevalence and characteristics of the metabolic syndrome in women with polycystic ovary syndrome

21 January 2018

1 reference

Adolescent girls with polycystic ovary syndrome have an increased risk of the metabolic syndrome associated with increasing androgen levels independent of obesity and insulin resistance

21 January 2018

1 reference

Increased insulin sensitivity and fibrinolytic capacity after dietary intervention in obese women with polycystic ovary syndrome.

21 January 2018

1 reference

Dietary composition in restoring reproductive and metabolic physiology in overweight women with polycystic ovary syndrome

21 January 2018

1 reference

Cardiovascular disease in women with polycystic ovary syndrome at long-term follow-up: a retrospective cohort study

21 January 2018

1 reference

Postmenopausal women with a history of irregular menses and elevated androgen measurements at high risk for worsening cardiovascular event-free survival: results from the National Institutes of Health--National Heart, Lung, and Blood Institute spons

21 January 2018

1 reference

Prediction of coronary events with electron beam computed tomography

21 January 2018

1 reference

Prevalence and predictors of coronary artery calcification in women with polycystic ovary syndrome

21 January 2018

1 reference

Evidence for an association between metabolic cardiovascular syndrome and coronary and aortic calcification among women with polycystic ovary syndrome

21 January 2018

1 reference

Young obese women with polycystic ovary syndrome have evidence of early coronary atherosclerosis.

21 January 2018

1 reference

Is there an independent effect of polycystic ovary syndrome (PCOS) and menopause on the prevalence of subclinical atherosclerosis in middle aged women?

21 January 2018

1 reference

Carotid atherosclerosis in women with polycystic ovary syndrome: initial results from a case-control study.

21 January 2018

1 reference

Endothelial dysfunction in PCOS: role of obesity and adipose hormones.

21 January 2018

1 reference

Association of hyperandrogenemic and metabolic phenotype with carotid intima-media thickness in young women with polycystic ovary syndrome

21 January 2018

1 reference

Early impairment of endothelial structure and function in young normal-weight women with polycystic ovary syndrome

21 January 2018

1 reference

The cardiovascular risk of young women with polycystic ovary syndrome: an observational, analytical, prospective case-control study

21 January 2018

1 reference

Diagnostic potential of serum N-terminal pro-B-type brain natriuretic peptide level in detection of cardiac wall stress in women with polycystic ovary syndrome: a cross-sectional comparison study.

21 January 2018

1 reference

Diastolic dysfunction and increased serum homocysteine concentrations may contribute to increased cardiovascular risk in patients with polycystic ovary syndrome.

21 January 2018

1 reference

Predictors of endothelial dysfunction in young women with polycystic ovary syndrome.

21 January 2018

1 reference

Early microvascular and macrovascular dysfunction is not accompanied by structural arterial injury in polycystic ovary syndrome.

21 January 2018

1 reference

Microvascular dysfunction in women with polycystic ovary syndrome

21 January 2018

1 reference

Severe endothelial dysfunction in young women with polycystic ovary syndrome is only partially explained by known cardiovascular risk factors.

21 January 2018

1 reference

Endothelial dysfunction in young women with polycystic ovary syndrome: relationship with insulin resistance and low-grade chronic inflammation

21 January 2018

1 reference

Polycystic ovary syndrome is associated with endothelial dysfunction

21 January 2018

1 reference

Endothelial function varies according to insulin resistance disease type.

21 January 2018

1 reference

Flow-mediated dilatation in overweight and obese women with polycystic ovary syndrome.

21 January 2018

1 reference

The relationship between heart rate variability and inflammatory markers in cardiovascular diseases

21 January 2018

1 reference

Interleukin 1 and tumor necrosis factor inhibit cardiac myocyte beta-adrenergic responsiveness

21 January 2018

1 reference

Tumor necrosis factor alpha (TNF alpha) is cardiodepressant in pathophysiologically relevant concentrations without inducing inducible nitric oxide-(NO)-synthase (iNOS) or triggering serious cytotoxicity

21 January 2018

1 reference

Prediction of mortality by high-sensitivity C-reactive protein and brain natriuretic peptide in patients with dilated cardiomyopathy

21 January 2018

1 reference

The role of IL-1 in the pathogenesis of heart disease.

21 January 2018

1 reference

A common interleukin-6 gene promoter polymorphism influences the clinical characteristics of women with polycystic ovary syndrome

21 January 2018

1 reference

Inflammation in chronic heart failure

21 January 2018

1 reference

C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women

21 January 2018

1 reference

Plasma concentration of interleukin-6 and the risk of future myocardial infarction among apparently healthy men.

21 January 2018

1 reference

Novel risk factors for systemic atherosclerosis: a comparison of C-reactive protein, fibrinogen, homocysteine, lipoprotein(a), and standard cholesterol screening as predictors of peripheral arterial disease

21 January 2018

1 reference

Systemic inflammation as a risk factor for atherothrombosis

21 January 2018

1 reference

Relationship between inflammation, insulin resistance and type 2 diabetes: 'cause or effect'?

21 January 2018

1 reference

Metabolic modulation of inflammation-induced activation of coagulation

21 January 2018

1 reference

Atherosclerosis — An Inflammatory Disease

21 January 2018

1 reference

MUC1 in human testis and ejaculated spermatozoa and its relationship to male fertility status

21 January 2018

1 reference

Cardiovascular risk in women with polycystic ovarian syndrome (PCOS)

21 January 2018

1 reference

Obesity, and not insulin resistance, is the major determinant of serum inflammatory cardiovascular risk markers in pre-menopausal women.

21 January 2018

1 reference

Insulin resistance causes impaired vasodilation and hypofibrinolysis in young women with polycystic ovary syndrome.

21 January 2018

1 reference

Indices of low-grade chronic inflammation in polycystic ovary syndrome and the beneficial effect of metformin

21 January 2018

1 reference

Soluble CD36 and risk markers of insulin resistance and atherosclerosis are elevated in polycystic ovary syndrome and significantly reduced during pioglitazone treatment.

21 January 2018

1 reference

The increase of leukocytes as a new putative marker of low-grade chronic inflammation and early cardiovascular risk in polycystic ovary syndrome

21 January 2018

1 reference

The polycystic ovary syndrome per se is not associated with increased chronic inflammation

21 January 2018

1 reference

Central fat excess in polycystic ovary syndrome: relation to low-grade inflammation and insulin resistance.

21 January 2018

1 reference

A specific elevation in tissue plasminogen activator antigen in women with polycystic ovarian syndrome

21 January 2018

1 reference

Platelet Dysfunction in Lean Women with Polycystic Ovary Syndrome and Association with Insulin Sensitivity

21 January 2018

1 reference

Serum adiponectin levels in women with polycystic ovary syndrome

21 January 2018

1 reference

Adiponectin is independently associated with insulin sensitivity in women with polycystic ovary syndrome.

21 January 2018

1 reference

Evidence for altered adipocyte function in polycystic ovary syndrome.

21 January 2018

1 reference

Circulating leptin concentrations in polycystic ovary syndrome: relation to anthropometric and metabolic parameters.

21 January 2018

1 reference

Serum resistin levels in women with polycystic ovary syndrome

21 January 2018

1 reference

Serum leptin elevation in obese women with PCOs: a continuing controversy

21 January 2018

1 reference

Serum and adipocyte resistin in polycystic ovary syndrome with insulin resistance

21 January 2018

1 reference

Serum leptin levels in patients with polycystic ovary syndrome

21 January 2018

1 reference

Leptin and the proinflammatory state associated with human obesity

21 January 2018

1 reference

Plasma interleukin 6 levels are elevated in polycystic ovary syndrome independently of obesity or sleep apnea

21 January 2018

1 reference

Serum interleukin-18 concentrations are increased in the polycystic ovary syndrome: relationship to insulin resistance and to obesity.

21 January 2018

1 reference

High neutrophil count in girls and women with hyperinsulinaemic hyperandrogenism: normalization with metformin and flutamide overcomes the aggravation by oral contraception

21 January 2018

1 reference

The role of low-grade inflammation in the polycystic ovary syndrome

21 January 2018

1 reference

Effect of weight loss and lifestyle changes on vascular inflammatory markers in obese women: a randomized trial

21 January 2018

1 reference

Modest weight loss and reduction in waist circumference after medical treatment are associated with favorable changes in serum adipocytokines.

21 January 2018

1 reference

C-reactive protein before and after weight loss in overweight women with and without polycystic ovary syndrome

21 January 2018

1 reference

Metformin reduces arterial stiffness and improves endothelial function in young women with polycystic ovary syndrome: a randomized, placebo-controlled, crossover trial

21 January 2018

1 reference

Effects of metformin with or without supplementation with folate on homocysteine levels and vascular endothelium of women with polycystic ovary syndrome

21 January 2018

1 reference

The effect of ethinylestradiol (EE)/cyproterone acetate (CA) and EE/CA plus metformin treatment on adhesion molecules in cases with polycystic ovary syndrome (PCOS).

21 January 2018

1 reference

Asymmetrical dimethylarginine, inflammatory and metabolic parameters in women with polycystic ovary syndrome before and after metformin treatment

21 January 2018

1 reference

Plasma cytokines in obese women with polycystic ovary syndrome, before and after metformin treatment

21 January 2018

1 reference

Metformin improves endothelial function in normoinsulinemic PCOS patients: a new prospective.

21 January 2018

1 reference

Metformin administration improves leukocyte count in women with polycystic ovary syndrome: a 6-month prospective study.

21 January 2018

1 reference

Metformin administration improves endothelial function in women with polycystic ovary syndrome

21 January 2018

1 reference

Improvement in endothelial structure and function after metformin treatment in young normal-weight women with polycystic ovary syndrome: results of a 6-month study

21 January 2018

1 reference

Metformin reduces serum C-reactive protein levels in women with polycystic ovary syndrome

21 January 2018

1 reference

Metformin therapy is associated with a decrease in plasma plasminogen activator inhibitor-1, lipoprotein(a), and immunoreactive insulin levels in patients with the polycystic ovary syndrome.

21 January 2018

1 reference

Effects of atorvastatin on vascular function, inflammation, and androgens in women with polycystic ovary syndrome: a double-blind, randomized, placebo-controlled trial.

21 January 2018

1 reference

Comparison of the effects of atorvastatin and simvastatin in women with polycystic ovary syndrome: A prospective, randomized study

21 January 2018

1 reference

The effect of atorvastatin in patients with polycystic ovary syndrome: a randomized double-blind placebo-controlled study.

21 January 2018

1 reference

Comparison of simvastatin and metformin in treatment of polycystic ovary syndrome: prospective randomized trial.

21 January 2018

1 reference

Improvement of endothelial function with metformin and rosiglitazone treatment in women with polycystic ovary syndrome

21 January 2018

1 reference

Effect of rosiglitazone on insulin resistance, C-reactive protein and endothelial function in non-obese young women with polycystic ovary syndrome

21 January 2018

1 reference

Troglitazone therapy improves endothelial function to near normal levels in women with polycystic ovary syndrome

21 January 2018

1 reference

Metformin Causes a Reduction in Basal and Post-venous Occlusion Plasminogen Activator Inhibitor-1 in Type 2 Diabetic Patients

21 January 2018

1 reference

Relationship Between C-Reactive Protein Levels and Regional Left Ventricular Function in Asymptomatic Individuals

21 January 2018

1 reference

Obesity and insulin resistance but not hyperandrogenism mediates vascular dysfunction in women with polycystic ovary syndrome

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1345/APH.1Q514

1 reference

26 August 2017

1 reference